« Return to News | Clinical Intelligence

YM BioSciences enrolls first patients in phase II CYT387 trial

Wednesday, September 28, 2011 12:42 PM

YM BioSciences has enrolled the first patients in its multi-center phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis. The trial will further evaluate the safety and tolerability of YM's JAK1/JAK2 inhibitor, as well as its  efficacy in reducing spleen size, improving constitutional symptoms and  reducing transfusion dependence in patients with myelofibrosis.

Six leading academic centers in the U.S. and Canada will recruit  approximately 60 patients in two phases: part I, a dose-escalation  study enrolling successive patient cohorts dosed starting at 200mg BID,  escalating at 50mg BID per cohort; and part II, a dose-confirmation  study evaluating patients at or below the maximum tolerated dose  determined in part I.  Patients in this trial will be evaluated for six 28-day cycles.

In the BID trial, spleen size will be evaluated both by palpation and by magnetic resonance imaging (MRI) for all patients enrolled.

Constitutional symptoms will be assessed using the Myelofibrosis  Symptom Assessment Form (MFSAF). Transfusion histories will be collected for the six-month period prior to enrollment and transfusion independence will be based on both 8-week and 12-week criteria. The effect of CYT387 on plasma levels of inflammatory, fibrogenic and  angiogenic cytokines, and on bone marrow and peripheral blood  cytogenetics will also be assessed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.